Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected ugandan children

Clinical Infectious Diseases

Volumn 59, Issue 3, 2014, Pages 446-453

  Kakuru, Abel ^a   Achan, Jane ^a   Muhindo, Mary K ^a   Ikilezi, Gloria ^a   Arinaitwe, Emmanuel ^a   Mwangwa, Florence ^a   Ruel, Theodore ^b   Clark, Tamara D ^b   Charlebois, Edwin ^b   Rosenthal, Philip J ^b   Havlir, Diane ^b   Kamya, Moses R ^a   Tappero, Jordan W ^c   Dorsey, Grant ^b  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

ACTs; ART; Children; HIV; Malaria

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; QUININE; STAVUDINE; ZIDOVUDINE; ANTIMALARIAL AGENT; ARTEMISININ; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; PIPERAQUINE; QUINOLINE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHILDHOOD DISEASE; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALAISE; MALARIA; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PARASITEMIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; COHORT ANALYSIS; COMBINATION DRUG THERAPY; CONTROLLED STUDY; HIV INFECTIONS; INFANT; PRESCHOOL CHILD; TREATMENT OUTCOME; UGANDA;

ANTIMALARIALS; ARTEMISININS; CHILD, PRESCHOOL; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INFANT; LOPINAVIR; MALARIA; MALE; NEVIRAPINE; PARASITEMIA; QUINOLINES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME; UGANDA;

EID: 84905027373     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu286     Document Type: Article

References (40)

1. World Health Organization. Country antimalarial drug policies: by region. Available at: http://www.who.int/malaria/am-drug-policies-by-region-afro/en/ index.html. Accessed 8 April 2013.
2. World Health Organization. World malaria report 2009. Available at: http://www.who.int/malaria/publications/atoz/9789241563901/en/. Accessed 9 April 2013.
3. Sagara I, Fofana B, Gaudart J, et al. Repeated artemisinin-based combination therapies in a malaria hyperendemic area of Mali: efficacy, safety, and public health impact. Am J Trop Med Hyg 2012; 87: 50-6.
4. Abuaku B, Duah N, Quaye L, Quashie N, Koram K. Therapeutic efficacy of artemether-lumefantrine combination in the treatment of uncomplicated malaria among children under five years of age in three ecological zones in Ghana. Malar J 2012; 11: 388.
5. Nambozi M, Van Geertruyden J-P, Hachizovu S, et al. Safety and efficacy of dihydroartemisinin-piperaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Zambian children. Malar J 2011; 10: 50.
6. Yavo W, Faye B, Kuete T, et al. Multicentric assessment of the efficacy and tolerability of dihydroartemisinin-piperaquine compared to artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in sub-Saharan Africa. Malar J 2011; 10: 198.
7. Ndiaye J-LA, Faye B, Gueye A, et al. Repeated treatment of recurrent uncomplicated Plasmodium falciparum malaria in Senegal with fixed-dose artesunate plus amodiaquine versus fixed-dose artemether plus lumefantrine: a randomized, open-label trial. Malar J 2011; 10: 237.
8. Ngasala BE, Malmberg M, Carlsson AM, et al. Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children <5 years of age with acute uncomplicated Plasmodium falciparum malaria in rural Tanzania: a randomized trial. Clin Infect Dis 2011; 52: 873-82.
9. Gargano N, Ubben D, Tommasini S, et al. Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malar J 2012; 11: 233.
10. Charle P, Berzosa P, Lucio A de, Raso J, Nchama GN, Benito A. Artesunate/amodiaquine malaria treatment for Equatorial Guinea (Central Africa). Am J Trop Med Hyg 2013; 88: 1087-92.
11. Anvikar AR, Sharma B, Shahi BH, et al. Artesunate-amodiaquine fixed dose combination for the treatment of Plasmodium falciparum malaria in India. Malar J 2012; 11: 97.
12. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008; 46: 985-91.
13. Byakika-Kibwika P, Ddumba E, Kamya M. Effect of HIV-1 infection on malaria treatment outcome in Ugandan patients. Afr Health Sci 2007; 7: 86-92.
14. Kamya MR, Gasasira AF, Yeka A, et al. Effect of HIV-1 infection on antimalarial treatment outcomes in Uganda: a population-based study. J Infect Dis 2006; 193: 9-15.
15. Geertruyden J-PV, Mulenga M, Mwananyanda L, et al. HIV-1 immune suppression and antimalarial treatment outcome in Zambian adults with uncomplicated malaria. J Infect Dis 2006; 194: 917-25.
16. Kamya MR, Kigonya CN, McFarland W. HIV infection may adversely affect clinical response to chloroquine therapy for uncomplicated malaria in children. AIDS 2001; 15: 1187-8.
17. Birku Y, Mekonnen E, Björkman A, Wolday D. Delayed clearance of Plasmodium falciparum in patients with human immunodeficiency virus co-infection treated with artemisinin. Ethiop Med J 2002; 40 (SUPPL. 1): 17-26.
18. Huang L, Parikh S, Rosenthal PJ, et al. Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lume-fantrine in healthy volunteers. J Acquir Immune Defic Syndr 2012; 61: 310-6.
19. Byakika-Kibwika P, Lamorde M, Mayito J, et al. Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 2012; 67: 2213-21.
20. German P, Parikh S, Lawrence J, et al. Lopinavir/ritonavir affects pharmacokinetic exposure of artemether/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 2009; 51: 424-9.
21. Achan J, Kakuru A, Ikilezi G, et al. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med 2012; 367: 2110-8.
22. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Available at: http://www.who.int/malaria/publications/atoz/9789241547925/en/ index.html. Accessed 10 May 2013.
23. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: http://www.who.int/hiv/pub/guidelines/arv2013/en/. Accessed 19 December 2013.
24. Okello PE, Bortel WV, Byaruhanga AM, et al. Variation in malaria transmission intensity in seven sites throughout Uganda. Am J Trop Med Hyg 2006; 75: 219-25.
25. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49: 1629-37.
26. Ikilezi G, Achan J, Kakuru A, et al. Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg 2013; 88: 744-6.
27. Sandison TG, Homsy J, Arinaitwe E, et al. Protective efficacy of cotrimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ 2011; 342.
28. Katrak S, Gasasira A, Arinaitwe E, et al. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J 2009; 8: 272.
29. Arinaitwe E, Gasasira A, Verret W, et al. The association between malnutrition and the incidence of malaria among young HIV-infected and -uninfected Ugandan children: a prospective study. Malar J 2012; 11: 90.
30. Kakuru A, Jagannathan P, Arinaitwe E, et al. The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children. Am J Trop Med Hyg 2013; 88: 736-43.
31. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Available at: http://www.who.int/malaria/publications/atoz/whohtmrbm200350/en/. Accessed 21 May 2013.
32. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009; 4: e7871.
33. Zwang J, Ashley EA, Karema C, et al. Safety and efficacy of dihydroartemisinin-piperaquine in falciparum malaria: a prospective multi-centre individual patient data analysis. PLoS One 2009; 4:e6358.
34. Lee TM-N, Huang L, Johnson MK, et al. In vitro metabolism of piperaquine is primarily mediated by CYP3A4. Xenobiotica 2012; 42: 1088-95.
35. Zhou S-F, Xue CC, Yu X-Q, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 2007; 29: 687-710.
36. Zhou S, Yung Chan S, Cher Goh B, et al. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet 2005; 44: 279-304.
37. Josephson F, Bertilsson L, Böttiger Y, et al. CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels. Eur J Clin Pharmacol 2008; 64: 775-81.
38. Fellay J, Marzolini C, Decosterd L, et al. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005; 60: 865-73.
39. Ma Q, Okusanya OO, Smith PF, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005; 1: 473-85.
40. Shubber Z, Calmy A, Andrieux-Meyer I, et al. Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. AIDS 2013; 27: 1403-12.